LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

Search

Cerus Corp

Ouvert

SecteurSoins de santé

1.34 0.75

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.32

Max

1.37

Chiffres clés

By Trading Economics

Revenu

-5.2M

-7.7M

Ventes

-7.6M

43M

BPA

-0.04

Marge bénéficiaire

-17.85

Employés

614

EBITDA

-5.8M

-5.9M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+243.38% upside

Dividendes

By Dow Jones

Prochains Résultats

31 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-3.8M

256M

Ouverture précédente

0.59

Clôture précédente

1.34

Sentiment de l'Actualité

By Acuity

67%

33%

338 / 380 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Cerus Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

26 juin 2025, 23:49 UTC

Résultats

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 juin 2025, 22:19 UTC

Acquisitions, Fusions, Rachats

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 juin 2025, 21:30 UTC

Résultats

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 juin 2025, 21:07 UTC

Résultats

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 juin 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 juin 2025, 23:39 UTC

Market Talk

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 juin 2025, 23:34 UTC

Acquisitions, Fusions, Rachats

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 juin 2025, 23:33 UTC

Acquisitions, Fusions, Rachats

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 juin 2025, 23:32 UTC

Acquisitions, Fusions, Rachats

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 juin 2025, 23:32 UTC

Acquisitions, Fusions, Rachats

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 juin 2025, 23:31 UTC

Acquisitions, Fusions, Rachats

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 juin 2025, 23:31 UTC

Acquisitions, Fusions, Rachats

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 juin 2025, 23:30 UTC

Acquisitions, Fusions, Rachats

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 juin 2025, 23:29 UTC

Acquisitions, Fusions, Rachats

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 juin 2025, 23:19 UTC

Acquisitions, Fusions, Rachats

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 juin 2025, 22:06 UTC

Résultats

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 juin 2025, 21:15 UTC

Résultats

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 juin 2025, 21:07 UTC

Acquisitions, Fusions, Rachats

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 juin 2025, 21:07 UTC

Acquisitions, Fusions, Rachats

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 juin 2025, 21:07 UTC

Acquisitions, Fusions, Rachats

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 juin 2025, 21:07 UTC

Résultats

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 juin 2025, 21:06 UTC

Acquisitions, Fusions, Rachats

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 juin 2025, 21:06 UTC

Acquisitions, Fusions, Rachats

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 juin 2025, 21:06 UTC

Market Talk

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 juin 2025, 21:05 UTC

Acquisitions, Fusions, Rachats

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 juin 2025, 21:05 UTC

Acquisitions, Fusions, Rachats

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 juin 2025, 20:52 UTC

Résultats

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 juin 2025, 20:51 UTC

Résultats

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 juin 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 juin 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Comparaison

Variation de prix

Cerus Corp prévision

Objectif de Prix

By TipRanks

243.38% hausse

Prévisions sur 12 Mois

Moyen 4.67 USD  243.38%

Haut 5 USD

Bas 4 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

3

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

1.3 / 1.36Support & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Strong Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

338 / 380Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Cerus Corp

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.